Type 1 diabetes affects topoisomerase i activity and GlcNAcylation in rat organs: Kidney, liver and pancreas

Glycobiology

Volumn 22, Issue 5, 2012, Pages 704-713

  Levi, Itzhak ^a   Segev, Yael ^a   Priel, Esther ^a  

^a BEN GURION UNIVERSITY OF THE NEGEV   (Israel)

Author keywords

hyperglycemia; O GlcNAc; O GlcNAc transferase; topoisomerase I; type I diabetes

Indexed keywords

DNA TOPOISOMERASE; N ACETYLGLUCOSAMINE; STREPTOZOCIN;

ACYLATION; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; ENZYME ACTIVITY; FEMALE; GENE EXPRESSION; HYPERGLYCEMIA; INSULIN DEPENDENT DIABETES MELLITUS; KIDNEY; LIVER; NONHUMAN; PANCREAS; PRIORITY JOURNAL; RAT;

ACYLATION; ANIMALS; DIABETES MELLITUS, TYPE 1; DNA TOPOISOMERASES, TYPE I; FEMALE; KIDNEY; LIVER; N-ACETYLGLUCOSAMINYLTRANSFERASES; PANCREAS; RATS; RATS, WISTAR;

ANIMALIA; RATTUS;

EID: 84859089877     PISSN: 09596658     EISSN: 14602423     Source Type: Journal    
DOI: 10.1093/glycob/cws008     Document Type: Article

References (38)

1. Akimoto Y, Hart GW, Hirano H, Kawakami H. 2005. O-GlcNAc modification of nucleocytoplasmic proteins and diabetes. Med Mol Morphol. 38:84-91
2. Auer B, Vosberg HP, Buhre U, Klocker H, Hirsch-Kauffmann M, Schweiger M. 1982. Intracellular distribution of DNA topoisomerase I in fibroblasts from patients with Fanconi's anaemia. Hum Genet. 61:369-371
3. Beckman JA, Creager MA, Libby P. 2002. Diabetes and atherosclerosis: Epidemiology, pathophysiology, and management. J Am Med Assoc. 287:2570-2581
4. Bendetz-Nezer S, Gazit A, Priel E. 2004. DNA topoisomerase I as one of the cellular targets of certain tyrphostin derivatives. Mol Pharmacol. 66:627-634
5. Bonnin S, Besson F, Gelhausen M, Chierici S, Roux B. 1999. A FTIR spectroscopy evidence of the interactions between wheat germ agglutinin and N-acetylglucosamine residues. FEBS Lett. 456:361-364
6. Brownlee M. 2001. Biochemistry and molecular cell biology of diabetic complications. Nature. 414:813-820
7. Champoux JJ. 2001. DNA topoisomerases: Structure, function, and mechanism. Annu Rev Biochem. 70:369-413
8. Couri CE, Voltarelli JC. 2008. Potential role of stem cell therapy in type 1 diabetes mellitus. Arq Bras Endocrinol Metabol. 52:407-415
9. Eisenbarth GS. 1986. Type I diabetes mellitus: A chronic autoimmune disease. N Engl J Med. 314:1360-1368
10. Sambrook J, Fritsch EF, Maniatis T. 1989. Molecular Cloning A Laboratory Manual. Cold Spring Harbor (NY): Cold Spring Harbor Laboratory Press.
11. Gao Y, Wells L, Comer FI, Parker GJ, Hart GW. 2001. Dynamic O-glycosylation of nuclear and cytosolic proteins: Cloning and characterization of a neutral, cytosolic beta-N-acetylglucosaminidase from human brain. J Biol Chem. 276:9838-9845
12. Girach A, Manner D, Porta M. 2006. Diabetic microvascular complications: Can patients at risk be identified? A review. Int J Clin Pract. 60:1471-1483
13. Kolm-Litty V, Sauer U, Nerlich A, Lehmann R, Schleicher ED. 1998. High glucose-induced transforming growth factor beta1 production is mediated by the hexosamine pathway in porcine glomerular mesangial cells. J Clin Invest. 101:160-169
14. Kreppel LK, Blomberg MA, Hart GW. 1997. Dynamic glycosylation of nuclear and cytosolic proteins: Cloning and characterization of a unique O-GlcNAc transferase with multiple tetratricopeptide repeats. J Biol Chem. 272:9308-9315
15. Lenzen S. 2008. The mechanisms of alloxan- and streptozotocin-induced diabetes. Diabetologia. 51:216-226
16. Leppard JB, Champoux JJ. 2005. Human DNA topoisomerase. I. Relaxation, roles, and damage control. Chromosoma. 114:75-85
17. Liu K, Paterson AJ, Chin E, Kudlow JE. 2000. Glucose stimulates protein modification by O-linked GlcNAc in pancreatic beta cells: Linkage of O-linked GlcNAc to beta cell death. Proc Natl Acad Sci USA. 97:2820-2825
18. Lubas WA, Hanover JA. 2000. Functional expression of O-linked GlcNAc transferase: Domain structure and substrate specificity. J Biol Chem. 275:10983-10988
19. Macauley MS, Whitworth GE, Debowski AW, Chin D, Vocadlo DJ. 2005. O-GlcNAcase uses substrate-assisted catalysis: Kinetic analysis and development of highly selective mechanism-inspired inhibitors. J Biol Chem. 280:25313-25322
20. Noach N, Segev Y, Levi I, Segal S, Priel E. 2007. Modification of topoisomerase I activity by glucose and by O-GlcNAcylation of the enzyme protein. Glycobiology. 17:1357-1364
21. Notkins AL. 2002. Immunologic and genetic factors in type 1 diabetes. J Biol Chem. 277:43545-43548
22. Notkins AL, Lernmark A. 2001. Autoimmune type 1 diabetes: Resolved and unresolved issues. J Clin Invest. 108:1247-1252
23. Plaschkes I, Silverman FW, Priel E. 2005. DNA topoisomerase I in the mouse central nervous system: Age and sex dependence. J Comp Neurol. 493:357-369
24. Pommier Y, Pourquier P, Fan Y, Strumberg D. 1998. Mechanism of action of eukaryotic DNA topoisomerase I and drugs targeted to the enzyme. Biochim Biophys Acta. 1400:83-105
25. Schrijvers BF, De Vriese AS, Flyvbjerg A. 2004a. From hyperglycemia to diabetic kidney disease: The role of metabolic, hemodynamic, intracellular factors and growth factors/cytokines. Endocrinol Rev. 25:971-1010
26. Schrijvers BF, De Vriese AS, Van de Voorde J, Rasch R, Lameire NH, Flyvbjerg A. 2004b. Long-term renal changes in the Goto-Kakizaki rat, a model of lean type 2 diabetes. Nephrol Dial Transplant. 19:1092-1097
27. Segev Y, Landau D, Marbach M, Shehadeh N, Flyvbjerg A, Phillip M. 1997. Renal hypertrophy in hyperglycemic non-obese diabetic mice is associated with persistent renal accumulation of insulin-like growth factor I. J Am Soc Nephrol. 8:436-444
28. Slawson C, Housley MP, Hart GW. 2006. O-GlcNAc cycling: How a single sugar post-translational modification is changing the way we think about signaling networks. J Cell Biochem. 97:71-83
29. van den Brand M, Elving LD, Drenth JP, van Krieken JH. 2009. Glycogenic hepatopathy: A rare cause of elevated serum transaminases in diabetes mellitus. Neth J Med. 67:394-396
30. Vosseller K, Wells L, Lane MD, Hart GW. 2002. Elevated nucleocytoplasmic glycosylation by O-GlcNAc results in insulin resistance associated with defects in Akt activation in 3T3-L1 adipocytes. Proc Natl Acad Sci USA. 99:5313-5318
31. Walgren JL, Vincent TS, Schey KL, Buse MG. 2003. High glucose and insulin promote O-GlcNAc modification of proteins, including alphatubulin. Am J Physiol Endocrinol Metab. 284:E424-E434.
32. Wang JC. 2002. Cellular roles of DNA topoisomerases: A molecular perspective. Nat Rev Mol Cell Biol. 3:430-440
33. Wells L, Vosseller K, Hart GW. 2001. Glycosylation of nucleocytoplasmic proteins: Signal transduction and O-GlcNAc. Science. 291:2376-2378
34. Wolf G, Ziyadeh FN. 1999. Molecular mechanisms of diabetic renal hypertrophy. Kidney Int. 56:393-405
35. Wu AM, Wu JH, Song SC, Tsai MS, Herp A. 1998. Studies on the binding of wheat germ agglutinin (Triticum vulgaris) to O-glycans. FEBS Lett. 440:315-319
36. Yagil C, Barak A, Ben-Dor D, Rosenmann E, Bernheim J, Rosner M, Segev Y, Weksler-Zangen S, Raz I, Yagil Y. 2005. Nonproteinuric diabetesassociated nephropathy in the Cohen rat model of type 2 diabetes. Diabetes. 54:1487-1496
37. Yki-Jarvinen H, Vogt C, Iozzo P, Pipek R, Daniels MC, Virkamaki A, Makimattila S, Mandarino L, DeFronzo RA, McClain D, et al. 1997. UDP-N-acetylglucosamine transferase and glutamine: Fructose 6-phosphate amidotransferase activities in insulin-sensitive tissues. Diabetologia. 40:76-81
38. Yu D, Khan E, Khaleque MA, Lee J, Laco G, Kohlhagen G, Kharbanda S, Cheng YC, Pommier Y, Bharti A. 2004. Phosphorylation of DNA topoisomerase I by the c-Abl tyrosine kinase confers camptothecin sensitivity. J Biol Chem. 279:51851-51861.